Groupe d'Etude en Oncologie du Quebec

Titre	A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers
Protocole ID	MK-9999-02A
ClinicalTrials.gov ID	NCT06428409
Type(s) de cancer	Colorectal Pancréas Voies biliaires
Phase	Phase I-II
Type étude	Clinique
Médicament	Sacituzumab tirumotecan seul ou avec de la chimiothérapie
Institution	CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
Ville	Montréal
Investigateur(trice) principal(e)	Dre Francine Aubin
Coordonnateur(trice)	Adeline Hamon 514-890-8000 poste 30737
Statut	Actif en recrutement
Critètes d'éligibilité	The main inclusion criteria include but are not limited to the following: Has one of the following cancers: Unresectable or metastatic colorectal cancer Advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) Advanced and/or unresectable biliary tract cancer (BTC) Has received prior therapy for the cancer Has recovered from any side effects due to previous cancer treatment
Critètes d'exclusion	The main exclusion criteria include but are not limited to the following: History of severe eye disease Received prior systemic anticancer therapy including investigational agents within 4 weeks before starting study intervention History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease

Groupe d'étude en oncologie du Québec